Zobrazeno 1 - 10
of 169
pro vyhledávání: ''
Autor:
Esther Pohl-Rescigno, Peter Klare, Gbg, Kristina Lübbe, Michael Untch, Kerstin Rhiem, Carsten Denkert, Jens Huober, Hans Tesch, Andreas Schneeweiss, Sibylle Loibl, Christian Jackisch, Karin Kast, Rita K. Schmutzler, Christine Solbach, Theresa Link, Valentina Nekljudova, L Michel, Peter A. Fasching, Claus Hanusch, Eric Hahnen, Volker Möbus, Ago-B, Jens-Uwe Blohmer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 160
Background GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to weekly paclitaxel/non-pegylated liposomal doxorubicin (plus carboplatin (PM(Cb) i
Autor:
Shugo Ueda, Yoshihiro Okita, Ryohei Kawabata, Sachiko Yamamoto, Tatsuya Okuno, Jin Matsuyama, Atsushi Takeno, Hisato Kawakami, Yukinori Kurokawa, Takayuki Kii, Taroh Satoh, Kazuhiro Yanagihara, Hiroki Hara, Junji Kawada, Shunji Endo, Yutaka Kimura, Toshio Shimokawa
Publikováno v:
European journal of cancer (Oxford, England : 1990). 154
Background There is no standard chemotherapy for esophageal squamous cell carcinoma (ESCC) refractory to first-line fluoropyrimidine- and platinum-based chemotherapy. We therefore performed a randomized, selection-design phase II trial to compare doc
Autor:
S. Rizzato, Marica Eoli, Roberta Rudà, Giuseppe Lombardi, Mario Caccesse, Paola Del Bianco, Toni Ibrahim, Alba A. Brandes, Francesco Pasqualetti, E. Bergo, Andrea Pace, Gian Luca De Salvo, Ivan Lolli, Giovanna Magni, Bruno Daniele, Vittorina Zagonel
Publikováno v:
European journal of cancer (Oxford, England : 1990). 155
Background The REGOMA trial showed that regorafenib significantly improved overall survival in patients with recurrent glioblastoma compared with lomustine. Patients treated with regorafenib experienced a higher occurrence of grade 3–4 drug-related
Autor:
Bernard Escudier, Pauline Gaignard, Constance Thibault, Jean-Yves Scoazec, Emeline Colomba, L. Cerbone, Lucia Carril-Ajuria, Aude Flechon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Paillerets, Cecile Vicier, Olivier Caron, Marine Guillaud-Bataille, Guillermo Velasco, Laurence Albiges, Stéphane Richard, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre
Publikováno v:
European journal of cancer (Oxford, England : 1990). 151
Purpose Fumarate hydratase–deficient (FHdef) renal cell carcinoma (RCC) is a rare entity associated with the hereditary leiomyomatosis and RCC syndrome with no standard therapy approved. The aim of this retrospective study was to evaluate the effic
Publikováno v:
European journal of cancer (Oxford, England : 1990). 145
Background Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast cancer (ABC) comparing aromatase inhibitors (AIs) versus the selective estrogen receptor modulator tamoxifen, each individually reported significantly lo
Autor:
Allen Eng Juh Yeoh, Jing J. Eng, Kean H. Chiew, Ah M. Tan, Germaine S.M. Liew, Shawn H. R. Lee, Koon Mian Foo, Cheryl C.C. Neoh, Joyce Ching Mei Lam, Yiong Huak Chan, Zelia Z.L. Seeto, Bernice L. Z. Oh, Zhi W. Chen, Thuan C. Quah
Publikováno v:
European journal of cancer (Oxford, England : 1990). 142
In non-high-risk (non-HR) patients, the Malaysia-Singapore Acute Lymphoblastic Leukaemia 2003 (MS2003) study achieved good outcomes. However, its delayed-intensification (DI) phase, comprising repeated blocks of protocol III (2003-PIII), was toxic an
Autor:
Sophie Postel-Vinay, Capucine Baldini, Jean C. Soria, David Malka, Anas Gazzah, Valérie Boige, Stéphane Champiat, Yolla El-Dakdoukti, Jean M. Michot, Christophe Massard, Antoine Hollebecque, P. Vuagnat, Michel Ducreux, Aurélien Marabelle, Samy Ammari, Andreea Varga, Rastislav Bahleda, Patricia Martin-Romano, Eric Angevin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 137
Background Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy (CT) are the current standard of therapy in several cancer types. Patients (pts) with lung cancer display higher response rates to CT when given after ICIs. Alth
Autor:
Olivier Raffy, Adrien Dixmier, Gérard Zalcman, Clara Fontaine-Delaruelle, Damien Pouessel, Olivier Molinier, Sandrine Hiret, Franck Morin, Patrick-Aldo Renault, Julien Mazieres, Charles Dayen, Patrick Dumont, Catherine Becht, Sylvestre Le Moulec, Eric Pichon, Benjamin Besse, Clarisse Audigier-Valette, Claire Poulet, Fabrice Barlesi, Alexis B. Cortot, Denis Moro-Sibilot, Alexandra Langlais
Publikováno v:
European journal of cancer (Oxford, England : 1990). 131
Purpose Second-line chemotherapy regimens have demonstrated poor benefit after failure of platinum-based chemotherapy in advanced non-squamous non–small-cell lung cancer (nsNSCLC). Methods In this multicentre, open-label phase III trial, patients w
Autor:
Yuji Miyamoto, Martin D. Berger, Chiara Cremolini, Madiha Naseem, Yan Ning, Diana L. Hanna, Marta Schirripa, Ryuma Tokunaga, Francesca Battaglin, Mitsukuni Suenaga, Sebastian Stintzing, Fotios Loupakis, Volker Heinemann, Heinz-Josef Lenz, Alberto Puccini, Shu Cao, Alfredo Falcone, Shivani Soni, Dongyun Yang, Wu Zhang
Publikováno v:
Eur J Cancer
Background Through enhancement of the Wnt signalling pathway, R-spondins are oncogenic drivers in colorectal cancer. Experimental data suggest that the R-spondin/Wnt axis stimulates vascular endothelial growth factor (VEGF)-dependent angiogenesis. We
Autor:
Lionel Geoffrois, David Pérol, Celine Ferlay, Ellen Blanc, Frederic Rolland, Alain Ravaud, Laurence Albiges, Gwenaelle Gravis, Marine Gross-Goupil, Bernard Escudier, Christine Chevreau, Slimane Dermeche, Aude Flechon, Nathalie Rioux-Leclercq, Sylvie Negrier, Helen Boyle
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
European Journal of Cancer, Elsevier, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
European Journal of Cancer, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
European Journal of Cancer, Elsevier, 2020, 129, pp.107-116. ⟨10.1016/j.ejca.2020.02.001⟩
International audience; Introduction: Papillary renal cell carcinoma (PRCC) represents 10%e15% of renal carcinomas. No standard treatments exist for metastatic PRCC (mPRCC) patients. Axitinib is indicated as second-line treatment in metastatic clear